Accepted for Publication: February 18, 2022.
Published: April 19, 2022. doi:10.1001/jamanetworkopen.2022.7852
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Nickols NG et al. JAMA Network Open.
Corresponding Author: Matthew B. Rettig, MD, Division of Hematology-Oncology, Department of Medicine, VA Greater Los Angeles Healthcare System, 11301 Wilshire Blvd, Los Angeles, CA 90073 (mrettig@mednet.ucla.edu).
Author Contributions: Drs Rettig and Nickols had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Nickols, Mi, Biswas, Clise, Becker, Makarov, Muthiah, Aguayo, Goetz, Graber, Soo Hoo, Norman, Tran, Tsai, Rettig.
Acquisition, analysis, or interpretation of data: Nickols, Mi, DeMatt, Clise, Huggins, Maraka, Levin, Ambrogini, Mirsaeidi, Levin, Becker, Makarov, Adorno Febles, Belligund, Al-Ajam, Muthiah, Montgomery, Robinson, Wong, Bedimo, Armamento-Villareal, Aguayo, Schoen, Graber, Bhattacharya, Soo Hoo, Orshansky, Ghayouri, Geelhoed, Rettig.
Drafting of the manuscript: Nickols, Mi, Clise, Becker, Aguayo, Tran, Ghayouri, Tsai, Geelhoed, Rettig.
Critical revision of the manuscript for important intellectual content: Nickols, Mi, DeMatt, Biswas, Huggins, Maraka, Ambrogini, Mirsaeidi, Levin, Becker, Makarov, Adorno Febles, Belligund, Al-Ajam, Muthiah, Montgomery, Robinson, Wong, Bedimo, Armamento-Villareal, Aguayo, Schoen, Goetz, Graber, Bhattacharya, Soo Hoo, Orshansky, Norman, Rettig.
Statistical analysis: Mi, DeMatt.
Obtained funding: Nickols, Rettig.
Administrative, technical, or material support: Nickols, Mi, Biswas, Clise, Ambrogini, Becker, Makarov, Adorno Febles, Belligund, Al-Ajam, Montgomery, Robinson, Wong, Bedimo, Aguayo, Schoen, Goetz, Graber, Soo Hoo, Norman, Tran, Ghayouri, Tsai, Geelhoed, Rettig.
Supervision: Nickols, Huggins, Maraka, Becker, Makarov, Robinson, Wong, Armamento-Villareal, Aguayo, Bhattacharya, Rettig.
Conflict of Interest Disclosures: Dr Nickols reported receiving grants from Lantheus, Bayer, and Janssen and personal fees from Oncolinea outside the submitted work. Dr Wong reported receiving grants from the Prostate Cancer Foundation during the conduct of the study. Dr Bedimo reported receiving grants from Merck and ViiV Healthcare and personal fees from Merck, ViiV Healthcare, Janssen, Gilead Sciences, and Theratechnologies outside the submitted work. Dr Rettig reported receiving grants from Johnson & Johnson, Bayer, and Pfizer and having a patent for Inhibitors of the N-Terminal Domain of the Androgen Receptor pending. No other disclosures were reported.
Funding/Support: The trial was funded by the Department of Veterans Affairs (VA) Office of Research and Development through a CSR&D Merit Review Award (Dr Rettig).
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 3.
Additional Information: Some VA sites in the trial were additionally supported by the Prostate Cancer Foundation as Centers of Excellence.
2.Davey
RA , Grossmann
M . Androgen receptor structure, function and biology: from bench to bedside.
Clin Biochem Rev. 2016;37(1):3-15.
PubMedGoogle Scholar 3.Deng
Q , Rasool
RU , Russell
RM , Natesan
R , Asangani
IA . Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19.
iScience. 2021;24(3):102254. doi:
10.1016/j.isci.2021.102254PubMedGoogle Scholar 4.Qiao
Y , Wang
XM , Mannan
R ,
et al. Targeting transcriptional regulation of SARS-CoV-2 entry factors
ACE2 and
TMPRSS2.
Proc Natl Acad Sci U S A. 2020;202021450. Published online December 11, 2020. doi:
10.1073/pnas.2021450118PubMedGoogle Scholar 10.McCoy
J , Goren
A , Cadegiani
FA ,
et al. Proxalutamide reduces the rate of hospitalization for covid-19 male outpatients: a randomized double-blinded placebo-controlled trial.
Front Med (Lausanne). 2021;8:668698. doi:
10.3389/fmed.2021.668698PubMedGoogle Scholar 11.Cadegiani
FA , McCoy
J , Gustavo Wambier
C ,
et al. Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19: results from a randomized, double-blinded, placebo-controlled trial.
Cureus. 2021;13(2):e13492. doi:
10.7759/cureus.13492PubMedGoogle Scholar 13.Rick
FG , Block
NL , Schally
AV . An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.
Onco Targets Ther. 2013;6:391-402. doi:
10.2147/OTT.S32426PubMedGoogle Scholar 14.Nickols
NG , Goetz
MB , Graber
CJ ,
et al. Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial.
Trials. 2021;22(1):431. doi:
10.1186/s13063-021-05389-0PubMedGoogle ScholarCrossref 17.Almoosa
KF , Gupta
A , Pedroza
C , Watts
NB . Low testosterone levels are frequent in patients with acute respiratory failure and are associated with poor outcomes.
Endocr Pract. 2014;20(10):1057-1063. doi:
10.4158/EP14003.ORPubMedGoogle ScholarCrossref 18.Bech
A , Van Leeuwen
H , De Boer
H . Etiology of low testosterone levels in male patients with severe sepsis requiring mechanical ventilation.
Crit Care. 2013;17(suppl 2):448. doi:
10.1186/cc12386Google ScholarCrossref 23.Stelzig
KE , Canepa-Escaro
F , Schiliro
M , Berdnikovs
S , Prakash
YS , Chiarella
SE . Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells.
Am J Physiol Lung Cell Mol Physiol. 2020;318(6):L1280-L1281. doi:
10.1152/ajplung.00153.2020PubMedGoogle ScholarCrossref